To include your compound in the COVID-19 Resource Center, submit it here.

Oral treprostinil: Preliminary Phase III data

Preliminary data from the double-blind, international Phase III FREEDOM-M trial in 228 evaluable patients showed that oral treprostinil met the primary endpoint of significantly improving median 6MWD from baseline to week 12

Read the full 329 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE